The article on therapeutic cloning ("Will Britain buy a therapeutic cell?", THES, February 25) gave a good account of the debate. But there were two errors. First, the Roslin Institute remains very much in the public sector; it is one of our spin-off firms, Roslin BioMed, that has been acquired by Geron. Second, we are based in Edinburgh, not Aberdeen.
H. D. Griffin Assistant director (science)Roslin Institute, Edinburgh